User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Non-invasive quantification of the beta cell mass by SPECT with 111In-labelled exendin

Primary tabs

Brom, Maarten Gotthardt, Martin Boerman, Otto C. Janssen, Marcel Tack, Cees J. Bouckenooghe, Thomas [UCL] Woliner-Van Der Weg, Wietske

Aims/hypothesis: A reliable method for in vivo quantification of pancreatic beta cell mass (BCM) could lead to further insight into the pathophysiology of diabetes. The glucagon-like peptide 1 receptor, abundantly expressed on beta cells, may be a suitable target for imaging. We investigated the potential of radiotracer imaging with the GLP-1 analogue exendin labelled with indium-111 for determination of BCM in vivo in a rodent model of beta cell loss and in patients with type 1 diabetes and healthy individuals. Methods : The targeting of 111In-labelled exendin was examined in a rat model of alloxan-induced beta cell loss. Rats were injected with 15 MBq 111In-labelled exendin and single photon emission computed tomography (SPECT) acquisition was performed 1 h post injection, followed by dissection, biodistribution and ex vivo autoradiography studies of pancreatic sections. BCM was determined by morphometric analysis after staining with an anti-insulin antibody. For clinical evaluation SPECT was acquired 4, 24 and 48 h after injection of 150 MBq 111In-labelled exendin in five patients with type 1 diabetes and five healthy individuals. The tracer uptake was determined by quantitative analysis of the SPECT images. Results : In rats, 111In-labelled exendin specifically targets the beta cells and pancreatic uptake is highly correlated with BCM. In humans, the pancreas was visible in SPECT images and the pancreatic uptake showed high interindividual variation with a substantially lower uptake in patients with type 1 diabetes. Conclusions : These studies indicate that 111In-labelled exendin may be suitable for non-invasive quantification of BCM.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2014
Language Anglais
Journal information "Diabetologia : clinical and experimental diabetes and metabolism" - Vol. 57, no. 5, p. 950-959 (2014)
Peer reviewed yes
Publisher Springer
e-issn 1432-0428
issn 0012-186X
Publication status Publié
Affiliations UCL - SST/ISV - Institut des sciences de la vie
UCL - SST/LIBST - Louvain Institute of Biomolecular Science and Technology
Links
  1. American Diabetes Association (2006) Diagnosis and classification of diabetes mellitus. Diabetes Care 29(Suppl 1):S43–S48
  2. L�hr M., Kl�ppel G., Residual insulin positivity and pancreatic atrophy in relation to duration of chronic Type 1 (insulin-dependent) diabetes mellitus and microangiopathy, 10.1007/bf00275740
  3. Steele C., Hagopian W. A., Gitelman S., Masharani U., Cavaghan M., Rother K. I., Donaldson D., Harlan D. M., Bluestone J., Herold K. C., Insulin Secretion in Type 1 Diabetes, 10.2337/diabetes.53.2.426
  4. Coppieters Ken T., Dotta Francesco, Amirian Natalie, Campbell Peter D., Kay Thomas W.H., Atkinson Mark A., Roep Bart O., von Herrath Matthias G., Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients, 10.1084/jem.20111187
  5. Klinke David J., Extent of Beta Cell Destruction Is Important but Insufficient to Predict the Onset of Type 1 Diabetes Mellitus, 10.1371/journal.pone.0001374
  6. Couri Carlos E. B., C-Peptide Levels and Insulin Independence Following Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus, 10.1001/jama.2009.470
  7. DeFronzo RA (1997) Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5:177–269
  8. Taylor Simeon I, Deconstructing Type 2 Diabetes, 10.1016/s0092-8674(00)80709-6
  9. Weir G. C., Bonner-Weir S., Five Stages of Evolving Beta-Cell Dysfunction During Progression to Diabetes, 10.2337/diabetes.53.suppl_3.s16
  10. Cnop M., Welsh N., Jonas J.-C., Jorns A., Lenzen S., Eizirik D. L., Mechanisms of Pancreatic  -Cell Death in Type 1 and Type 2 Diabetes: Many Differences, Few Similarities, 10.2337/diabetes.54.suppl_2.s97
  11. Butler A. E., Janson J., Bonner-Weir S., Ritzel R., Rizza R. A., Butler P. C.,  -Cell Deficit and Increased  -Cell Apoptosis in Humans With Type 2 Diabetes, 10.2337/diabetes.52.1.102
  12. Ritzel R. A., Butler A. E., Rizza R. A., Veldhuis J. D., Butler P. C., Relationship Between  -Cell Mass and Fasting Blood Glucose Concentration in Humans, 10.2337/diacare.29.03.06.dc05-1538
  13. Korner M., Stockli M., Waser B., Reubi J. C., GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting, 10.2967/jnumed.106.038679
  14. Tornehave Ditte, Kristensen Peter, Rømer John, Knudsen Lotte Bjerre, Heller R. Scott, Expression of the GLP-1 Receptor in Mouse, Rat, and Human Pancreas, 10.1369/jhc.2008.951319
  15. Brom Maarten, Oyen Wim J. G., Joosten Lieke, Gotthardt Martin, Boerman Otto C., 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET, 10.1007/s00259-009-1363-y
  16. Wang Yi, Lim Keunpoong, Normandin Marc, Zhao Xiaojian, Cline Gary W., Ding Yu-Shin, Synthesis and evaluation of [18F]exendin (9–39) as a potential biomarker to measure pancreatic β-cell mass, 10.1016/j.nucmedbio.2011.07.011
  17. Wild D., Wicki A., Mansi R., Behe M., Keil B., Bernhardt P., Christofori G., Ell P. J., Macke H. R., Exendin-4-Based Radiopharmaceuticals for Glucagonlike Peptide-1 Receptor PET/CT and SPECT/CT, 10.2967/jnumed.110.074914
  18. Wu Z., Liu S., Hassink M., Nair I., Park R., Li L., Todorov I., Fox J. M., Li Z., Shively J. E., Conti P. S., Kandeel F., Development and Evaluation of 18F-TTCO-Cys40-Exendin-4: A PET Probe for Imaging Transplanted Islets, 10.2967/jnumed.112.109694
  19. Wu Zhanhong, Todorov Ivan, Li Lin, Bading James R., Li Zibo, Nair Indu, Ishiyama Kohei, Colcher David, Conti Peter E., Fraser Scott E., Shively John E., Kandeel Fouad, In Vivo Imaging of Transplanted Islets with64Cu-DO3A-VS-Cys40-Exendin-4 by Targeting GLP-1 Receptor, 10.1021/bc200132t
  20. Heskamp S., van Laarhoven H. W. M., Molkenboer-Kuenen J. D. M., Franssen G. M., Versleijen-Jonkers Y. M. H., Oyen W. J. G., van der Graaf W. T. A., Boerman O. C., ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model, 10.2967/jnumed.110.075648
  21. Rademakers Saskia E., Rijken Paul F., Peeters Wenny J., Nijkamp Monique M., Barber Paul R., van der Laak Jeroen, van de Kogel Albert J., Bussink Johan, Kaanders Johannes H., Parametric mapping of immunohistochemically stained tissue sections; a method to quantify the colocalization of tumor markers, 10.1007/s13402-010-0008-2
  22. Rijken Paul F.J.W., Bernsen Hans J.J.A., van der Kogel Albert J., Application of an Image Analysis System to the Quantitation of Tumor Perfusion and Vascularity in Human Glioma Xenografts, 10.1006/mvre.1995.1048
  23. Garofano A., Czernichow P., Bréant B., Beta-cell mass and proliferation following late fetal and early postnatal malnutrition in the rat, 10.1007/s001250051038
  24. Chen Chun-Ming, Behringer Richard R., Cloning, Structure, and Expression of the Mouse Ovca1 Gene, 10.1006/bbrc.2001.5488
  25. Cunha D. A., Hekerman P., Ladriere L., Bazarra-Castro A., Ortis F., Wakeham M. C., Moore F., Rasschaert J., Cardozo A. K., Bellomo E., Overbergh L., Mathieu C., Lupi R., Hai T., Herchuelz A., Marchetti P., Rutter G. A., Eizirik D. L., Cnop M., Initiation and execution of lipotoxic ER stress in pancreatic  -cells, 10.1242/jcs.026062
  26. Overbergh Lut, Valckx Dirk, Waer Mark, Mathieu Chantal, QUANTIFICATION OF MURINE CYTOKINE mRNAs USING REAL TIME QUANTITATIVE REVERSE TRANSCRIPTASE PCR, 10.1006/cyto.1998.0426
  27. Nock Berthold A., Nikolopoulou Anastasia, Galanis Athanassios, Cordopatis Paul, Waser Beatrice, Reubi Jean-Claude, Maina Theodosia, Potent Bombesin-like Peptides for GRP-Receptor Targeting of Tumors with99mTc:  A Preclinical Study, 10.1021/jm049437y
  28. Maina T, Nock BA, Zhang H et al (2005) Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J Nucl Med 46:823–830
  29. Jensen R. T., Moody T., Pert C., Rivier J. E., Gardner J. D., Interaction of bombesin and litorin with specific membrane receptors on pancreatic acinar cells, 10.1073/pnas.75.12.6139
  30. Moran Timothy H., Moody Terry W., Hostetler Anne M., Robinson Paul H., Goldrich Michael, McHugh Paul R., Distribution of bombesin binding sites in the rat gastrointestinal tract, 10.1016/0196-9781(88)90177-5
  31. Brom Maarten, Joosten Lieke, Oyen Wim J. G., Gotthardt Martin, Boerman Otto C., Radiolabelled GLP-1 analogues forin vivotargeting of insulinomas : RADIOLABELLED GLP-1 ANALOGUES FOR GLP-1R TARGETING, 10.1002/cmmi.475
  32. Reiner T., Thurber G., Gaglia J., Vinegoni C., Liew C. W., Upadhyay R., Kohler R. H., Li L., Kulkarni R. N., Benoist C., Mathis D., Weissleder R., Accurate measurement of pancreatic islet  -cell mass using a second-generation fluorescent exendin-4 analog, 10.1073/pnas.1109859108
  33. Xu Gang, Kaneto Hideaki, Lopez-Avalos Maria D., Weir Gordon C., Bonner-Weir Susan, GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts, 10.1016/j.diabres.2005.11.007
  34. Brom Maarten, Andraojc Karolina, J.G. Oyen Wim, C. Boerman Otto, Gotthardt Martin, Development of Radiotracers for the Determination of the Beta-Cell Mass In Vivo, 10.2174/138161210791164126
  35. Xu G., Kaneto H., Laybutt D. R., Duvivier-Kali V. F., Trivedi N., Suzuma K., King G. L., Weir G. C., Bonner-Weir S., Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia: Possible Contribution to Impaired Incretin Effects in Diabetes, 10.2337/db06-1033
  36. Rahier J., Guiot Y., Goebbels R. M., Sempoux C., Henquin J. C., Pancreatic β-cell mass in European subjects with type 2 diabetes, 10.1111/j.1463-1326.2008.00969.x
  37. Moore A., Bonner-Weir S., Weissleder R., Noninvasive In Vivo Measurement of  -Cell Mass in Mouse Model of Diabetes, 10.2337/diabetes.50.10.2231
  38. Freeby M., Goland R., Ichise M., Maffei A., Leibel R., Harris P., VMAT2 quantitation by PET as a biomarker for β-cell mass in health and disease, 10.1111/j.1463-1326.2008.00943.x
  39. Goland R., Freeby M., Parsey R., Saisho Y., Kumar D., Simpson N., Hirsch J., Prince M., Maffei A., Mann J. J., Butler P. C., Van Heertum R., Leibel R. L., Ichise M., Harris P. E., 11C-Dihydrotetrabenazine PET of the Pancreas in Subjects with Long-Standing Type 1 Diabetes and in Healthy Controls, 10.2967/jnumed.108.054866
  40. de Lonlay Pascale, Simon-Carre Aurore, Ribeiro Maria-João, Boddaert Nathalie, Giurgea Irina, Laborde Kathleen, Bellanné-Chantelot Christine, Verkarre Virginie, Polak Michel, Rahier Jacques, Syrota André, Seidenwurm David, Nihoul-Fékété Claire, Robert Jean-Jacques, Brunelle Francis, Jaubert Francis, Congenital Hyperinsulinism: Pancreatic [18F]Fluoro-l-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography and Immunohistochemistry Study of DOPA Decarboxylase and Insulin Secretion, 10.1210/jc.2005-1713
  41. Hardy Olga T., Hernandez-Pampaloni Miguel, Saffer Janet R., Suchi Mariko, Ruchelli Eduardo, Zhuang Hongming, Ganguly Arupa, Freifelder Richard, Adzick N. Scott, Alavi Abass, Stanley Charles A., Diagnosis and Localization of Focal Congenital Hyperinsulinism by 18F-Fluorodopa PET Scan, 10.1016/j.jpeds.2006.08.028
  42. Otonkoski T., Nanto-Salonen K., Seppanen M., Veijola R., Huopio H., Hussain K., Tapanainen P., Eskola O., Parkkola R., Ekstrom K., Guiot Y., Rahier J., Laakso M., Rintala R., Nuutila P., Minn H., Noninvasive Diagnosis of Focal Hyperinsulinism of Infancy With [18F]-DOPA Positron Emission Tomography, 10.2337/diabetes.55.01.06.db05-1128
  43. Rubí Blanca, Ljubicic Sanda, Pournourmohammadi Shirin, Carobbio Stefania, Armanet Mathieu, Bartley Clarissa, Maechler Pierre, Dopamine D2-like Receptors Are Expressed in Pancreatic Beta Cells and Mediate Inhibition of Insulin Secretion, 10.1074/jbc.m505560200
  44. Sweet Ian R, Cook Daniel L, Lernmark Åke, Greenbaum Carla J, Wallen Angela R, Marcum Erin S, Stekhova Svetlana A, Krohn Kenneth A, Systematic screening of potential β-cell imaging agents, 10.1016/j.bbrc.2003.12.182
  45. Normandin M. D., Petersen K. F., Ding Y.-S., Lin S.-F., Naik S., Fowles K., Skovronsky D. M., Herold K. C., McCarthy T. J., Calle R. A., Carson R. E., Treadway J. L., Cline G. W., In Vivo Imaging of Endogenous Pancreatic  -Cell Mass in Healthy and Type 1 Diabetic Subjects Using 18F-Fluoropropyl-Dihydrotetrabenazine and PET, 10.2967/jnumed.111.100545
  46. Freeby Matthew, Ichise Masanori, Harris Paul E., Vesicular monoamine transporter, type 2 (vmat2) expression as it compares to insulin and pancreatic polypeptide in the head, body and tail of the human pancreas, 10.4161/isl.22995
Bibliographic reference Brom, Maarten ; Gotthardt, Martin ; Boerman, Otto C. ; Janssen, Marcel ; Tack, Cees J. ; et. al. Non-invasive quantification of the beta cell mass by SPECT with 111In-labelled exendin. In: Diabetologia : clinical and experimental diabetes and metabolism, Vol. 57, no. 5, p. 950-959 (2014)
Permanent URL http://hdl.handle.net/2078.1/159811